Posts Archive

MEDEA S.r.l. is the ThrombUS+ partner leading exploitation strategy, IP management, and impact assurance to bring AI-powered DVT monitoring technology to market.

Meet VDE, ThrombUS+’s regulatory partner. Learn how VDE is embedding compliance-by-design into the development of an AI-powered wearable for early DVT detection.

Hôpital Simone Veil, the only French partner in ThrombUS+, brings cutting-edge venous thrombosis research and emergency medicine expertise to the consortium.

How do you build an AI medical device that meets EU MDR and AI Act requirements? Regulatory expert Thorsten Prinz of ThrombUS+ partner VDE explains the roadmap to compliance.

Founded by Saint Pio in 1956, Casa Sollievo della Sofferenza combines compassionate care and scientific excellence. Now a leading Italian Research Hospital (IRCCS), it contributes specialized expertise in pregnancy-related thrombosis to the ThrombUS+ European Project.

Tasked with creating a novel device for the early detection of DVT, ThrombUS+ made great strides in 2025 including new prototypes, the initiation of clinical trials, and advancements in scientific research.

Papageorgiou General Hospital is one of the largest and most prestigious hospitals in Greece, and a major partner involved in the Clinical Studies of the ThrombUS+ project. ThrombUS+ is tasked with creating a wearable device for the autonomous detection of deep vein thrombosis.

The Lithuanian University of Health Sciences (LSMU), one of Europe's largest life sciences universities with over 8,000 students, contributes as the clinical partner to the ThrombUS+ Horizon Europe project developing innovative wearable technology for deep vein thrombosis detection and monitoring.